Migraine Pipeline Space Brims with Novel Emerging Therapies with Over 30 Pharma Players Working in the Domain |DelveInsight

The Migraine Pipeline landscape is robust and fueled with new therapies which hold the promise to change the migraine treatment regimen in coming years.

Los Angeles, USA, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Migraine Pipeline Space Brims with Novel Emerging Therapies with Over 30 Pharma Players Working in the Domain |DelveInsight

The Migraine Pipeline landscape is robust and fueled with new therapies which hold the promise to change the migraine treatment regimen in coming years.

DelveInsight's 'Migraine Pipeline Insights' report offers comprehensive coverage of the emerging Migraine therapies in different stages of clinical trials from pre-clinical till a late-end stage, along with dormant, inactive and abandoned drugs agents.

The Migraine Pipeline report offers a complete view of the ongoing clinical trials, partnerships taking place in the domain, recent happenings in space and opportunities along with the hurdles across the Migraine Pipeline domain.

Some of the key highlights from the Migraine Pipeline report:

• The Migraine Pipeline report offers a rich analysis of 30+ key players and 30+ key therapies.

• Migraine pipeline comprises therapies in different stages of the clinical phase such as include Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, AbbVie, Eli Lilly and Company, Allodynic Therapeutics, Trevena, AEON Biopharma, Sosei Heptares, Vaxxinity, Pulmatrix, Pear Therapeutics, BetterLife Pharma, and others, with many others expected to enter the Migraine market in the coming next decade.

• Some of the key companies engaged in strengthening the Migraine Pipeline are Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, Pear Therapeutics, among others.

• In June 2021, Sosei Group Corporation announced the initiation of Phase I clinical study of HTL0022562 (also known as BHV3100), a novel, small-molecule CGRP receptor antagonist, for the treatment of migraine. (NCT04941989)

• In March 2021, AbbVie announced that the US FDA accepted a new drug application (NDA) for atogepant for the preventive treatment of Migraines. The NDA approval was supported by data from a pivotal Phase III ADVANCE clinical trial, a pivotal Phase IIb/III study, and a Phase III long-term safety study.

• In March 2021, Biohaven Pharmaceutical enrolled the first subject in Phase II/III clinical trial of oral zavegepant for the preventive treatment of migraine (NCT04804033).

Request for Sample to know more about the emerging therapy anticipated to grab maximum patient pool @ Migraine Emerging Therapies and Forecast

Migraine is a medical condition that causes severe, recurring headaches and other symptoms such as tingling sensations, flashing lights, weird sounds, and blurred or lost vision. The condition has no cure; however, treatments are available, including pain relief over-the-counter (OTC) drugs.

For more information on emerging drugs, visit Migraine Pipeline Analysis

Migraine Pipeline Drugs

Drug	Company	Phase	MoA	RoA
Zavegepant	Biohaven Pharmaceuticals	Phase III	Calcitonin gene-related peptide receptor antagonists	Oral/Intranasal
STS-101	Satsuma Pharmaceuticals	Phase III	Serotonin 1B receptor agonists	Intranasal
Atogepant	AbbVie	Preregistration	Calcitonin gene-related peptide antagonists	Oral
LY-3451838	Eli Lilly and Company	Phase II	Pituitary adenylate cyclase-activating polypeptide receptor antagonists	Intravenous
ALLOD 2	Allodynic Therapeutics	Phase II/III	Cyclo-oxygenase 2 inhibitors	Oral
TRV-250	Trevena	Phase II	Opioid delta receptor agonists	Subcutaneous
Prabotulinumtoxin A	AEON Biopharma	Phase II	Acetylcholine inhibitors	Intramuscular
HTL 0022562	Sosei Heptares	Phase I	Calcitonin gene-related peptide antagonists	Subcutaneous
UB 313	Vaxxinity	Preclinical	Calcitonin gene-related peptide receptor antagonists	NA

Request for Sample to know more @ Migraine Pipeline Analysis, Key Companies, and Futuristic Trends

Migraine Therapeutic Assessment

The Migraine Pipeline report lays down complete insights into active Migraine emerging therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.

By Product Type

• Mono

• Combination

By Stage

• Discovery

• Pre-clinical

• IND

• Phase I

• Phase II

• Phase III

• Pre-registration

By Molecule Type

• Vaccines

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

By Route of Administration

• Intramuscular

• Intranasal

• Oral

• Subcutaneous

• Intravenous

By Mechanism of Action

• Calcitonin gene-related peptide receptor antagonists

• Serotonin 1B receptor agonists

• Pituitary adenylate cyclase-activating polypeptide receptor antagonists

• Cyclo-oxygenase 2 inhibitors

• Opioid delta receptor agonists

• Acetylcholine inhibitors

By Targets

• Calcitonin gene-related peptide receptor

• Serotonin 1B receptor

• Pituitary adenylate cyclase-activating polypeptide receptor

• Cyclo-oxygenase 2

• Opioid delta receptor

• Acetylcholine

Get in touch with our Business executive for Informative Business Decisions, In/Out-Licensing Services, Drug Portfolio Management and Consulting Solutions

Scope of the Migraine Pipeline Report

Coverage: Global
Key Players: Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, AbbVie, Eli Lilly and Company, Allodynic Therapeutics, Trevena, AEON Biopharma, Sosei Heptares, Vaxxinity, Pulmatrix, Pear Therapeutics, BetterLife Pharma, and others.
Key Migraine Pipeline Therapies: Zavegepant, STS-101, Atogepant, LY-3451838, ALLOD 2, TRV-250, Prabotulinumtoxin A, HTL 0022562, UB 313, PUR-3100, TD 0148A, and others.

Reach out @ Migraine Pipeline: Novel therapies and Emerging technologies

Table of Contents

1	Report Introduction
2	Migraine Disease Overview
3	Migraine Pipeline Outlook
4	Comparative Analysis
5	Migraine Therapeutic Products in Clinical Stage
6	Migraine Late Stage Products (Phase III)
7	Migraine Mid Stage Products (Phase II)
8	Migraine Early Stage Products (Phase I)
9	Migraine Therapeutic Products in Non-clinical Stage
10	Migraine Preclinical and Discovery Stage Products
11	Migraine – DelveInsight’s Analytical Perspective
12	In-depth Commercial Assessment
13	Migraine Collaboration Deals
14	Migraine Therapeutics Pipeline Analysis
15	Inactive Migraine Pipeline Products
16	Migraine Key Companies
17	Migraine- Unmet Needs
18	Migraine Market Drivers and Barriers
19	Migraine- Future Perspectives and Conclusion
20	Appendix
21	Report Methodology
22	Consulting Services
23	Disclaimer
24	About DelveInsight

Visit to know more of what's covered @ Migraine Emerging Therapies, Treatments and Ongoing Clinical Trials

Related Reports

Migraine Market
DelveInsight's 'Migraine – Market Insights, Epidemiology, and Market Forecast —2030' report.

Brain Hemorrhage Market
DelveInsight's "Brain Hemorrhage - Market Insights, Epidemiology, and Market Forecast-2030" report.

Charcot Marie Tooth Disease Market
DelveInsight's 'Charcot–Marie–Tooth Disease -Market Insights, Epidemiology, and Market Forecast –2030' report.

Chronic Pain Market
DelveInsight's 'Chronic Pain - Market Insights, Epidemiology, and Market Forecast—2030' report.

Chronic Traumatic Encephalopathy Market
DelveInsight's "Chronic Traumatic Encephalopathy (CTE) - Market Insights, Epidemiology, and Market Forecast-2030" report.

Cluster Headache Market
DelveInsight's 'Cluster Headache Market Insights, Epidemiology, and Market Forecast—2030' report

Browse through blog posts
Migraine Market
Neurological Disorders and Recent Breakthroughs in the Market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News

CONTACT: Contact Us Shruti Thakur info@delveinsight.com +1(919)321-6187 www.delveinsight.com